Development of the Safe and Broad-Spectrum Aldehyde and Ketoamide Mpro inhibitors Derived from the Constrained α, γ-AA Peptide Scaffold

Keyphrases

• Aldehydes 100%
• Peptide Scaffold 100%
• α-ketoamides 100%
• COVID-19 100%
• Main Protease Inhibitor 100%
• Main Protease 50%
• SARS-CoV-2 Main Protease 50%
• Coronavirus 25%
• Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 25%
• Peptidomimetics 25%
• X-ray Crystallography 25%
• High Mortality 25%
• Morbidity Mortality 25%
• Inhibitory Activity 25%
• Peptide-based 25%
• Antiviral Activity 25%
• Covalent Bond 25%
• Enzymatic Assay 25%
• Molecular Scaffold 25%
• Havoc 25%
• Active Target 25%
• Middle East Respiratory Syndrome Coronavirus (MERS-CoV) 25%
• HCoV-NL63 25%
• Human Coronavirus (HCoV) 25%
• HCoV-OC43 25%
• HCoV-229E 25%
• HKU1 25%
• Antiviral Development 25%

Chemistry

• Peptidomimetic 100%
• Covalent Bond 100%
• Fluorescence Resonance Energy Transfer 100%
• Molecular Scaffold 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Proteinase Inhibitor 100%
• SARS Coronavirus 100%
• Proteinase 57%
• Peptidomimetic Agent 14%
• Antivirus Agent 14%
• Covalent Bond 14%
• Lead Compound 14%
• Antiviral Activity 14%
• Molecular Scaffold 14%
• Middle East Respiratory Syndrome Coronavirus 14%